Concord Drugs
Concord Drugs Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Concord Drugs
Start SIPConcord Drugs Investment Rating
-
Master Rating:
-
Concord Drugs has an operating revenue of Rs. 55.24 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 4% needs improvement, ROE of 5% is fair but needs improvement. The company has a reasonable debt to equity of 9%, which signals a healthy balance sheet. From an O'Neil Methodology perspective, the stock has an EPS Rank of 43 which is a POOR score indicating inconsistency in earnings, a RS Rating of 39 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 91 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|
Oper Rev Qtr Cr | 14 | 14 | 13 | 15 |
Operating Expenses Qtr Cr | 12 | 13 | 12 | 15 |
Operating Profit Qtr Cr | 1 | 1 | 1 | 1 |
Depreciation Qtr Cr | 0 | 1 | 0 | 0 |
Interest Qtr Cr | 0 | 0 | 0 | 0 |
Tax Qtr Cr | 0 | 0 | 0 | 0 |
Net Profit Qtr Cr | 0 | 0 | 0 | 0 |
Concord Drugs Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 16
- 20 Day
- 27.88
- 50 Day
- 29.24
- 100 Day
- 30.1
- 200 Day
- 30.24
- 20 Day
- 27.85
- 50 Day
- 29.69
- 100 Day
- 31.1
- 200 Day
- 29.88
Concord Drugs Resistance and Support
Resistance | |
---|---|
First Resistance | 26.74 |
Second Resistance | 27.33 |
Third Resistance | 27.65 |
RSI | 40.18 |
MFI | 23.29 |
MACD Single Line | -0.75 |
MACD | -0.83 |
Support | |
---|---|
First Resistance | 25.83 |
Second Resistance | 25.51 |
Third Resistance | 24.92 |
Concord Drugs Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 4,472 | 340,990 | 76.25 |
Week | 3,686 | 313,786 | 85.12 |
1 Month | 2,772 | 228,444 | 82.4 |
6 Month | 8,604 | 509,450 | 59.21 |
Concord Drugs Result Highlights
Concord Drugs Synopsis
BSE-Medical-Diversified
Concord Drugs belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 58.96 Cr. and Equity Capital is Rs. 8.74 Cr. for the Year ended 31/03/2022. Concord Drugs Ltd. is a Public Limited Listed company incorporated on 24/04/1995 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24230TG1995PLC020093 and registration number is 020093.Market Cap | 23 |
Sales | 55 |
Shares in Float | 0.45 |
No of funds | |
Yield |
Book Value | 0.82 |
U/D Vol ratio | 0.6 |
LTDebt / Equity | 9 |
Alpha | 0.02 |
Beta | 0.21 |
Concord Drugs
Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
---|---|---|---|---|
Promoters | 49% | 49% | 49% | |
Individual Investors | 50.71% | 50.67% | 50.67% | |
Others | 0.29% | 0.33% | 0.33% |
Concord Drugs Management
Name | Designation |
---|---|
Mr. S Nagi Reddy | Chairman & Managing Director |
Mr. S Koni Reddy | WholeTime Director & CFO |
Mr. S Manoj Kumar Reddy | Whole Time Director |
Mr. S Nagavenkata Hareesh | Independent Director |
Mr. K Ramachandra Reddy | Independent Director |
Ms. Sumeela Kasu | Independent Director |
Concord Drugs Forecast
Price Estimates
Concord Drugs FAQs
What is Share Price of Concord Drugs ?
Concord Drugs share price is ₹26 As on 25 March, 2023 | 05:49
What is the Market Cap of Concord Drugs ?
The Market Cap of Concord Drugs is ₹23.1 Cr As on 25 March, 2023 | 05:49
What is the P/E ratio of Concord Drugs ?
The P/E ratio of Concord Drugs is 27.2 As on 25 March, 2023 | 05:49
What is the PB ratio of Concord Drugs ?
The PB ratio of Concord Drugs is 0.8 As on 25 March, 2023 | 05:49